Efficacy and Safety of Anti-interleukin (IL) 23 and Janus Kinase (JAK) Inhibitors with Drs. William J. Sandborn and Jessica R. Allegretti
2021-03-16
0:00
16:48
In this podcast, expert clinicians will discuss new evidence on investigational agents, the anti-IL-23 and JAK inhibitors, that are in late-stage development for treating moderate to severe CD.
Fler avsnitt från "MedEdTalks - Gastroenterology"
Missa inte ett avsnitt av “MedEdTalks - Gastroenterology” och prenumerera på det i GetPodcast-appen.